Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Merger Divestitures: Some Buyers Fail To Replace Generic Products

Executive Summary

US FTC analysis of merger remedy orders finds that of 42 on-market generic products that required manufacturing transfer, the buyer was unable to continue to sell 15 products.

You may also be interested in...



Celgene's Otezla Sale Shows FTC Wants Merging Companies To Ditch Marketed, Not Pipeline, Products

Companies used to be able to pick which overlapping products to divest to get US Federal Trade Commission merger approval but an FTC study showed certain divestitures weren't working.

Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth

Record-setting divestment order driven by sheer number of products where firms competed, not size of company that would result from acquisition.

Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products

The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel